Trials / Unknown
UnknownNCT04440917
Camrelizumab Combined With Apatinib Mesylate for Head and Neck Squamous Cell Carcinoma
Induction Therapy of Camrelizumab Combined With Apatinib Mesylate for Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (the IMplus Study)
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 32 (estimated)
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, open-labelled study to evaluate the efficacy and safety of camrelizumab combined with apatinib mesylate in the induction treatment of patients with locally advanced head and neck squamous cell carcinoma who were judged surgically unresectable or appropriate for non-surgical definitive therapy. The objective response rate (ORR) and safety will be evaluated as the primary endpoints, the 2-year overall survival (OS) rate and progression free survival (PFS) rate will be the second endpoints.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Camrelizumab | 200mg, iv, on day 1, 15, 29, 43 |
| DRUG | Apatinib Mesylate | 250 mg po, qd, 28 days as a cycle, 2 cycles in total |
Timeline
- Start date
- 2020-06-03
- Primary completion
- 2022-06-01
- Completion
- 2023-12-01
- First posted
- 2020-06-22
- Last updated
- 2021-02-02
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04440917. Inclusion in this directory is not an endorsement.